Silver Book Fact

“Knowing that his disease had a high cure rate, Ben Dacus felt a sense of security at a time of great uncertainty. In 1988 he was diagnosed with Hodgkin’s disease.

Strangely enough, Ben’s reaction to his diagnosis was one of relief. ‘I was relieved to know my illness had a name, and because of the high cure rate, I never really feared that I was going to die. Hodgkin’s had a long history of research, and doctors had been treating it succesfully for many year.’

When radiation treatments didn’t work, Ben was devastated. But to his relief chemotherapy afforded him a rapid recovery.

Looking back on his illness, Ben says he is thankful for medical research. ‘It didn’t occur to me at the time I was going through treatment to consider how medical research had brought treatment methods to the point it had. But I was thankful to live in a day and age when cancer is treatable. If it had been the 1950s, I would have died four years later.”

Investment in Research Saves Lives and Money. http://www.researchamerica.org/advocacy/investment.html. Published 2005

Reference

Title
Investment in Research Saves Lives and Money
Publisher
Research!America
Publication Date
Published 2005
Authors
Research!America
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A 2002 study found that image-guided percutaneous needle biopsies are between 3 and 7 times more cost-effective than open surgical biopsies, require a shorter procedure time, result in fewer infections,…  
  • According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development is for glioblastoma. The medicine singles out and latches onto the receptors on…  
  • Gains in healthy years of life and social value from cancer R&D
     
  • As of July 2014, 18 anticancer drugs received FDA approval after being designated breakthrough therapies.  
  • Imatinib, the first chemical agent to target a cancer-specific protein, improved 5-year survival rates for chromosome-positive chronic myelogenous leukemia (CML) from 17% in the mid-1970s to 63% in 2007.